(Reuters) – GlaxoSmithKline (NYSE:GSK) sued Moderna (NASDAQ:MRNA) in Delaware federal court on Tuesday for allegedly violating GSK’s patent rights in messenger RNA (mRNA) technology with its blockbuster COVID-19 vaccine Spikevax.
The lawsuit said Moderna’s lipid nanoparticles for transporting mRNA into the human body infringe several GSK patents covering similar innovations. GSK filed a related lawsuit against Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) in the same court in April over their COVID-19 vaccines.
This post appeared first on investing.com
